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ABSTRACT
Objective A recent large-scale study in multiple
sclerosis (MS) using the ImmunoChip platform reported
on 11 loci that showed suggestive genetic association
with MS. Additional data in sufficiently sized and
independent data sets are needed to assess whether
these loci represent genuine MS risk factors.
Methods The lead SNPs of all 11 loci were genotyped
in 10 796 MS cases and 10 793 controls from Germany,
Spain, France, the Netherlands, Austria and Russia, that
were independent from the previously reported cohorts.
Association analyses were performed using logistic
regression based on an additive model. Summary effect
size estimates were calculated using fixed-effect meta-
analysis.
Results Seven of the 11 tested SNPs showed significant
association with MS susceptibility in the 21 589 individuals
analysed here. Meta-analysis across our and previously
published MS case-control data (total sample size
n=101 683) revealed novel genome-wide significant
association with MS susceptibility (p<5×10−8) for all seven
variants. This included SNPs in or near LOC100506457
(rs1534422, p=4.03×10−12), CD28 (rs6435203,
p=1.35×10−9), LPP (rs4686953, p=3.35×10−8), ETS1
(rs3809006, p=7.74×10−9), DLEU1 (rs806349,
p=8.14×10−12), LPIN3 (rs6072343, p=7.16×10−12) and
IFNGR2 (rs9808753, p=4.40×10−10). Cis expression
quantitative locus effects were observed in silico for
rs6435203 on CD28 and for rs9808753 on several
immunologically relevant genes in the IFNGR2 locus.
Conclusions This study adds seven loci to the list of
genuine MS genetic risk factors and further extends the
list of established loci shared across autoimmune
diseases.
INTRODUCTION
Multiple sclerosis (MS) is the most common auto-
inflammatory disease of the central nervous system.
It is caused by the action and interaction of genetic
and environmental factors. Genome-wide associ-
ation studies (GWAS) and other large-scale geno-
typing projects have revealed that only few
common genetic variants exist that exert relatively
large effects (ie, OR ranging from ∼1.3 to 3), all of
which are located in the HLA (human leucocyte
antigen) locus (reviewed in ref. 1). The remainder
of the genetic risk spectrum is likely determined by
a large number of susceptibility variants exerting
much smaller effects. The hitherto completed
GWAS and follow-up projects have identified 110
independent SNPs outside the HLA locus showing
genome-wide significant association (p<5×10−8)
with MS risk (eg, refs 2–4). The most recent of
these studies using the ImmunoChip (a customised
genotyping array with extensive coverage of loci
involved in immune system disorders, including
MS5) in the discovery phase and previous GWAS
data for validation of top results reported on 48
novel genome-wide significant (p<5×10−8) MS
risk loci in a total of 29 300 MS cases and 50 794
controls.4 Eleven additional loci showed suggestive
evidence for association in the combined data
(p<1×10−6) but failed to surpass the genome-wide
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significance threshold.4 To address the question whether and
which of these suggestive loci possibly represent genuine MS
susceptibility factors, we genotyped the most significant SNP
originally highlighted4 in each of the 11 loci (table 1) using an
independent, multicentric case-control data set of 10 796 MS
cases and 10 793 controls. This included 18 335 individuals of
European descent from Austria, France, Germany, the
Netherlands and Spain, as well as 3254 subjects from Russia
(see online supplement 1: table e-1). None of these data sets
were previously analysed for the 11 SNPs under scrutiny here.
Association results from all 21 589 individuals were subse-
quently combined with those from the ImmunoChip study,4
amounting to a total of 101 683 subjects, the largest data set
collectively analysed in MS genetics to date.
METHODS
Subjects
The effective sample size available for analysis after quality
control (QC) comprised 21 589 individuals including 9079 MS
cases and 9256 unrelated controls of European descent from
Austria, France, Germany, the Netherlands and Spain, as well as
1717 cases and 1537 controls from three regions in Russia (see
online supplement 1: table e-1) and have been described previ-
ously.3 6 7 Diagnosis of MS was established according to stand-
ard diagnostic criteria.8 9 All samples were collected with
informed written consent. None of the samples tested here were
included in the previous ImmunoChip study.
Power analyses
Power analyses were performed using the Genetic Power
Calculator10 assuming a disease prevalence of 0.1% and no
between-study heterogeneity. The combined effective validation
data sets of 10 796 cases and 10 793 unrelated controls had
>80% power to detect an OR of 1.10 at a one-sided type-1
error rate of α=4.5×10−3 and down to allele frequencies of
0.16. The combined data sets of the original4 and of this study
across 101 683 individuals had >80% power to detect an OR
of 1.10 at a two-sided genome-wide type-1 error rate of
α=5×10−8 down to allele frequencies of 0.10.
Genotyping and quality control
Genotyping for all samples except the Dutch data set (see
below) was performed at the individual sites using single-assay
allelic discrimination assays based on TaqMan chemistry follow-
ing the manufacturer’s instructions (Life Technologies). Taqman
assays and reagents were ordered centrally by the Berlin site and
either used there or distributed to all participating centres. The
three Russian data sets were all genotyped at the site in
Novosibirsk, Russia, and all German samples were genotyped in
Berlin. Up to 5% of samples were genotyped in duplicate across
plates to assess genotyping accuracy. Genotypes in the Dutch
sample were generated on the Human610-Quad Bead GWAS
array (Illumina) and subjected to standard QC using the
GenABEL package in R (http://www.genabel.org/packages/
GenABEL). This entailed excluding samples showing ≥2% miss-
ingness, cryptic relatedness, and excess heterozygosity as well as
SNPs showing ≥2% missingness, or deviation from
Hardy-Weinberg equilibrium (HWE) at p>1×10−6. Principal
component analyses did not reveal ethnic outliers when plotting
Dutch and CEU HapMap samples together. For all data sets
included in this study, individuals with missing genotypes for
more than three SNPs were excluded prior to analysis (applic-
able to a total of 193 samples (∼0.9%) across all data sets). The
threshold for genotyping efficiency per SNP and data set was set
to >95%. SNPs falling under this threshold were rs6072343 (in
the Russia Novosibirsk and Yakutsk data sets), rs727098 and
rs9808753 (Russia-Yakutsk). HWE was assessed in controls and
deviations from HWE were defined as p<4.5×10−3 in each
data set (ie, applying a Bonferroni correction for 11 tests) based
on Pearson’s χ2 as implemented in PLINK V.1.07,11 which led
to the exclusion of rs806349 from the French data set. All other
SNPs passed these QC thresholds and were included in the
actual association analyses. Genotyping accuracy based on com-
parison with duplicated samples was >99.8% and total geno-
typing efficiency was >98% for each SNP after QC.
Association analyses
Association analyses were performed using PLINK and in the R
environment and were based on logistic regression using an
additive genetic model. The Dutch data set was adjusted for the
first four principal components. Based on recent recommenda-
tions for rare diseases including MS,12 the logistic regression
analyses were not adjusted for known covariates such as age
and sex. Meta-analyses across all data sets included here were
based on fixed-effect models. The experiment-wide significance
threshold was set to p<4.5×10−3 (ie, applying a Bonferroni
correction for 11 tests). Between-study heterogeneity was quan-
tified using the I2 metric, and statistical significance was
assessed using the Q test statistic. Significant evidence for
heterogeneity was defined as p<0.1, a threshold commonly
used in this context.13 14 Forest plots were generated using a
customised version of the ‘rmeta’ package in R.15 The data sets
of the original study4 and this study were combined using
fixed-effect meta-analysis. For this purpose, ancestry-adjusted
summary ORs and 95% CIs of the discovery and replication
data sets were extracted from the online supplementary table
S2 of the original study.4 In addition, differences between the
summary effect size estimates of the eight western European
data sets and the three data sets from Russia were assessed
by interaction analysis as previously described.16 For these
analyses, significance was defined as p<4.5×10−3 (ie,
Bonferroni-corrected for 11 tests). All meta-analysis p values of
the validation data sets only are reported as one-sided with
regards to the direction of effect reported in the original study.4
p Values for all other tests (ie, heterogeneity, the meta-analysis
of the original study4 and this study, interaction analyses) are
two-sided.
In silico fine-mapping of putative causal variants
We applied a recently developed in silico fine-mapping
algorithm (the ‘probabilistic identification of causal SNPs’
approach (PICS), http://www.broadinstitute.org/pubs/fine
mapping/?q=pics)17 to all seven genome-wide significantly asso-
ciated MS risk SNPs. PICS was developed based on
ImmunoChip data to estimate a SNP’s probability of being
‘causal’ in densely mapped genotyping data based on the associ-
ation result of the most significant SNP.17
RESULTS
Among the 11 candidate SNPs assessed in 21 589 individuals
across 11 data sets, six showed significant association with MS
susceptibility after Bonferroni correction (ie, pcorr<4.5×10
−3,
table 1, figure 1). These six SNPs were: rs1534422 in
LOC100506457 (OR=1.10, p=1.39×10−6), rs6435203 down-
stream of CD28 (OR=1.08, p=7.20×10−4), rs3809006 in
ETS1 (OR=1.07, p=1.26×10−3), rs806349 in DLEU1
(OR=1.12, p=9.80×10−8), rs6072343 upstream of LPIN3
(OR=1.14, p=1.14×10−5) and rs9808753 in IFNGR2
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Table 1 Association results of the 11 loci and MS risk assessed in 21 589 subjects of European descent
This study Original study 4 Combined
SNP Location (hg38) Nearest gene N MAF OR (95% CI) p Value* I2 (95% CI) PQ OR p Value† OR p Value†
rs1534422 (G/A) chr2:12,500,615 LOC100506457 11 44.3 1.10 (1.06 to 1.15) 1.39×10−6 0 (0 to 56) 0.530 1.06 2.49×10−7 1.07 4.03×10−12
rs6435203 (G/A) chr2:203,746,472 CD28 11 29.5 1.08 (1.03 to 1.13) 7.20×10−4 32 (0 to 67) 0.142 1.07 1.23×10−7 1.07 1.35×10−9
rs9846396 (T/C) chr3:141,422,126 ZBTB38 11 40.4 1.03 (0.99 to 1.08) 0.0560 0 (0 to 54) 0.575 1.07 7.77×10−8 1.10 5.94×10−8
rs4686953 (G/A)‡ chr3:188,365,131 LPP 11 45.5 1.05 (1.01 to 1.10) 6.00×10−3 0 (0 to 52) 0.603 1.06 2.26×10−7 1.06 3.35×10−8
rs727098 (C/T) chr6:139,590,185 DQ571824 10 24.8 1.02 (0.97 to 1.07) 0.254 0 (0 to 53) 0.609 1.07 6.49×10−7 1.06 2.20×10−6
rs13260060 (A/G) chr8:70,306,125 NCOA2 11 10.8 1.06 (0.99 to 1.13) 0.0444 9 (0 to 48) 0.357 1.10 7.40×10−7 1.09 2.37×10−7
rs3004212 (T/C) chr10:43,147,362 CSGALNACT2 11 26.1 1.04 (0.99 to 1.09) 0.0640 0 (0 to 0) 0.976 1.07 2.99×10−7 1.06 3.01×10−7
rs3809006 (G/A) chr11:128,540,941 ETS1 11 48.2 1.07 (1.02 to 1.11) 1.26×10−3 38 (0 to 69) 0.0978 1.06 3.51×10−7 1.06 7.74×10−9
rs806349 (T/C) chr13:50,285,854 DLEU1 10 46.7 1.12 (1.07 to 1.16) 9.80×10−8 54 (6 to 77) 0.0213 1.06 7.85×10−7 1.07 8.14×10−12
rs6072343 (A/G) chr20:41,339,548 LPIN3 9 13.7 1.14 (1.07 to 1.22) 1.14×10−5 38 (0 to 72) 0.112 1.09 7.13×10−8 1.11 7.16×10−12
rs9808753 (G/A) chr21:33,415,005 IFNGR2 10 11.7 1.12 (1.05 to 1.19) 2.62×10−4 0 (0 to 61) 0.423 1.09 1.26×10−7 1.10 4.40×10−10
Fixed effect meta-analysis results for the SNPs tested across all validation data sets and after combining the results of the original4 and of this study were performed using R. Allele names are displayed as minor/major allele based on control frequencies
across all validation data sets. The underlined allele name corresponds to the risk allele. The Bonferroni-corrected threshold for significant association in the validation data sets was set to p=4.5×10−3 to account for 11 tests; upon combining all data sets
from the original4 and validation study, the threshold to define significance was set to p=5×10−8, that is, corresponding to genome-wide significance. Underlined p values indicate experiment-wide significance for the validation data sets or genome-wide
significance for the meta-analysis of all available data. The locations are annotated based on the human genome build 38 (hg38) and the nearest gene has been determined according to RefGene as annotated on the UCSC (University of California,
Southern California) Genome Browser. Note that the nearest gene does not necessarily represent the functional element underlying the genetic association.
*One-sided with respect to the effect direction of the original study,4
†Two-sided.
‡This SNP was listed with archive ID rs66756607 in the original publication.4
I2, estimate of percentage of between-study heterogeneity that is beyond chance; MAF, minor allele frequency in controls across all validation datasets (in %); MS, multiple sclerosis; N, number of validation data sets after quality control; PQ, p value


























(OR=1.12, p=2.62×10−4). In addition, rs4686953 in LPP
(OR=1.05, p=6.00×10−3) missed the threshold for
experiment-wide multiple testing correction (pcorr<4.5×10
−3)
by a small margin. All of these seven loci showed genome-wide
significant (p<5×10−8) association with MS risk upon
meta-analysis of all available data, that is, after combining the
results from the original study4 and from the 11 independent
data sets tested here, amounting to a total of 101 683 indivi-
duals (table 1).
Furthermore, while the effect size estimates of the four
remaining loci showed non-significant effects in the combined
validation data sets after multiple testing correction (with p
values ranging from 0.254 to 0.0444, table 1, see online supple-
ment 1: figure e-1), all pointed into the same direction of effect
as in the original study (4) (p=0.0625 based on the underlying
binomial distribution) with ORs ranging from 1.02 to 1.06. The
corresponding 95% CIs of the ORs computed here included the
effect size estimates of the original study4 in all instances.
However, none of the four variants reached genome-wide sig-
nificance upon meta-analysis across all 101 683 available indivi-
duals (table 1).
For two of the 11 tested SNPs, there was weak evidence for
between-study heterogeneity in the validation data, that is,
rs806349 in DLEU1 (pQ=0.0210) and rs3809006 in ETS1
(pQ=0.0978; table 1). Accordingly, the 95% CIs of the I
2 esti-
mates were large in both instances (ie, 6–77 for rs806349 and
0–69 for rs3809006). The heterogeneity for rs806349 was pri-
marily due to heterogeneity of effect size estimates pointing into
the same direction of effect rather than heterogeneity of ORs
on either side of the null (figure 1E) and for rs3809006, this
was due to the single outlying estimate of the
Russian-Novosibirsk study pointing into the opposite direction
of effect than the majority of data sets (I2=0 (95% CI 0 to 46),
pQ=0.709 upon exclusion of this data set). Finally, interaction
analyses of the effect size estimates of the stratified western
European and Russian data sets did not yield any significant dif-
ferences after correction for 11 tests (pcorr<4.5×10
−3, see
online supplement 1: table e-2). The only SNP approaching this
threshold was rs3809006 in ETS1 (pinteraction=9.7×10
−3)
showing ORs of 1.09 (95% CI 1.04 to 1.14) in the western
European and 0.94 (95% CI 0.85 to 1.04) in the Russian data
sets (which was due to the single outlying effect estimate from
the Russia-Novosibirsk data set as described above).
To pinpoint the putative causal variant(s) underlying the
newly identified association signals we applied the PICS algo-
rithm17 to all seven SNPs showing genome-wide significant
association with MS. This revealed a number of variants (with
r2≥0.8 to the index SNPs) that had 80% or more cumulative
probability of including the causal variant per locus (median
number of SNPs per locus 16, range 5–31; see online supple-
ment 2). Interestingly, in all seven instances the index SNPs
showed the highest probability of representing the causal variant
(median probability=23.3%, range 7.2–29.1%, see online sup-
plement 2). Gene ontology (using category ‘biological process’)
terms and/or Biocarta pathways were available for four (ie,
CD28, LPP, IFNGR2 and ETS1) of the nearest genes for all
seven loci. Three of these (ie, all except LPP to which generally
only few gene ontology terms could be attributed) suggested a
functional involvement in processes related to the immune
system (see online supplement 1: table e-3).
DISCUSSION
Our study represents the first to show genome-wide significant
association between risk for MS and common genetic variants
in or near LOC100506457, CD28, ETS1, DLEU1, LPIN3,
IFNGR2 and LPP. All of these SNPs showed experiment-wide
and/or genome-wide significant association in the large collec-
tion of newly analysed samples (21 589 subjects) and upon com-
bining our data with those from previous efforts4 (resulting in a
total of 101 683 subjects), respectively. Overall, these results
provide compelling evidence that the highlighted loci represent
genuine genetic risk factors for MS and should be considered in
future genetic, functional and clinical studies. Moreover, our
study represents one of the few MS genetic association studies
in data sets from Russia. Our analyses show that effect size esti-
mates in this population are not substantially different from
those from western European data sets, at least not for the 11
SNPs that were analysed here.
In addition to considerably extending the list of established
genetic risk factors for MS, our study also represents an import-
ant step forward in extending the list of genetic factors shared
among autoimmune diseases. This is based on the observation
that six of the seven SNPs showing genome-wide significant
association with MS here also show considerable evidence for
association with several other autoimmune diseases, for
example, coeliac disease, autoimmune thyroiditis and type 1 dia-
betes (table 2). This observation is in line with previous reports
also suggesting putative involvements of the then established
MS risk loci in other autoimmune diseases (eg, refs 1 4 18).
This entirely independent evidence provides further indirect
support for a genuine involvement of these loci in MS patho-
genesis. Interestingly, the direction of effect was not always the
Figure 1 Meta-analyses of validation data sets showing genome-wide significant association between the putative loci and multiple sclerosis (MS)
risk upon combination of all data. The x axis depicts the OR. Study-specific ORs (black squares) and 95% CIs (lines) were calculated using an
additive model. The summary ORs and 95% CIs (grey diamonds) were calculated based on fixed-effect meta-analysis.
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same as for MS. This was most noticeable for CD28 where the
effect direction was inverse in MS compared with all other four
autoimmune diseases (table 2). Such inverse effect directions
across autoimmune diseases have been described previously.18 19
Furthermore, for CD28, LPP and ETS1 several SNPs beyond the
index SNP show genome-wide significant association with
coeliac disease, autoimmune thyroiditis and/or type 1 diabetes.
In all cases, the association of the non-index SNPs was statistic-
ally stronger than the association of the index SNP possibly sug-
gesting allelic heterogeneity across the disease entities assessed
here (table 2).
Despite the compelling accumulated genetic evidence for 7
out of the 11 loci tested and highlighted here, there are several
potential limitations to our study. First, despite having examined
a sample size of over 21 500 individuals in the data sets newly
genotyped here and over 101 500 subjects in the analyses com-
bining our data with those from the ImmunoChip study,4 power
was still limited to detect very small effect sizes (ie, ORs<1.10),
especially for minor allele frequencies below 0.20. In this
context it is noteworthy that the effect size estimates of the four
loci that did not reach genome-wide significance in the com-
bined meta-analyses all pointed into the same direction in the
validation data sets when compared with the original study.4
Thus, based on the currently available data, we cannot exclude
the possibility that some or all of the loci currently not display-
ing genome-wide significant evidence for association with MS
risk may eventually also prove to be genuine disease loci once
tested in even larger data sets. Second, this is the first study to
examine the 11 putative MS risk loci of interest here in data sets
of Russian origin. While to our knowledge we examined all MS
case-control data sets currently available from Russia, their com-
bined size of 3254 individuals is still comparatively small. Thus,
these results need to be interpreted carefully. This also includes
the analyses comparing effect size estimates between these and
western European samples: currently there is—with the poten-
tial exception of rs3809006 in ETS1—no strong evidence sug-
gesting that the genetic effects exerted by these 11 SNPs are
different in the Russian population when compared with the
western European population, but larger data sets are needed to
assess this question more thoroughly. In this context, it can also
not be excluded that population substructure may have affected
some of the association results. However, genome-wide SNP
data to assess and adjust for population substructure in the
Russian data sets tested here are currently not available. This
also applies to most of the western European data sets as only
the Dutch data set was adjusted for ethnic substructure.
However, the Dutch effect size estimates were similar to the
remaining western European data sets suggesting that
Table 2 Genetic association results of the 11 putative MS loci in other autoimmune diseases
Locus Index SNP
Index SNP associations in other
autoimmune diseases with p≤0.05
Best genome-wide significant SNP per
locus across other autoimmune diseases
LOC100506457 rs1534422 (G) ATD: OR=1.17 (G), p=1.76E-07
T1D: OR=1.09 (G), p=9.82E-06
CEL: OR=1.05 (G), p=0.0122
JIA: OR=1.13 (G), p=0.0215
–
CD28 rs6435203 (A) CEL: OR=1.14 (G), p=2.63E-10
RA :OR=1.06 (G), p=2.55E-03
T1D: OR=1.06 (G), p=4.27E-03
NAR: OR=1.10 (G), p=0.0134
ATD: rs11571297, OR=1.37 (A), p=2.09E-23
T1D: rs3087243, OR=1.19 (G), p=7.36E-21
CEL: rs1980422, OR=1.19 (C), p=1.43E-15
ZBTB38 rs9846396 (C) PBC: OR=1.11 (C), p=1.07E-03 –
LPP rs4686953* (G) CEL: OR=1.30 (A), p=2.979E-43
ATD: p=5.77E-06
CEL: rs2030519, OR=1.32 (A), p=3.00E-49
ATD: rs13093110, p=3.69E-08
DQ571824 rs727098 (C) T1D: OR=1.04 (C), p=0.0361 –
NCOA2 rs13260060 (A) PSO: OR=1.08 (A), p=0.0275
RA: OR=1.07 (A), p=0.0253
–
CSGALNACT2 rs3004212† (C) – –
ETS1 rs3809006 (G) CEL: OR=1.10 (G), p=5.36E-07
PSO: OR=1.14 (G), p=5.32E-04
ATD: p=0.0118
NAR: OR=1.09 (A), p=0.0187
CEL: rs61907765, OR=1.18 (T), p=3.43E-13
DLEU1 rs806349 (T) CEL: OR=1.05 (C), p=0.0119
ATD: p=0.0228
PBC: OR=1.07 (T), p=0.0255
–
LPIN3 rs6072343 (A) PBC: OR=1.14 (A), p=1.90E-03
T1D: OR=1.07 (A), p=0.0124
ATD: p=0.0314
–
IFNGR2 rs9808753 (G) PBC: OR=1.14 (G), p=2.46E-03
RA: OR=1.08 (A), p=3.93E-03
PSO: OR=1.12 (A), p=0.0141
–
This table displays genetic association results of the 11 loci from ImmunoChip studies of eight other autoimmune diseases as available on the ImmunoBase database (http://www.
immunobase.org). The ‘index SNP’ indicates the most significant SNP in the MS ImmunoChip study.4 The risk allele for each specific disease is listed in brackets if available at
ImmunoBase (https://www.immunobase.org/downloads/protected_data/iChip_Data/). Underlined allele names of the index SNP indicate directions of effect inverse to the one observed
for MS. Effect size estimates and effect directions were not available for autoimmune thyroid disease (ATD) on Immunobase; instead, for SNPs rs1534422 and rs11571297 they were
retrieved from the original study.26 The last column lists the most significant SNP per disease for loci (defined as ±1 Mb around the index SNP) that show genome-wide significant
association with the specific disease. Dark grey background indicates loci that did not replicate in this study.
*For the diseases ATD and T1D, results for a proxy SNP were available in ImmunoBase (rs2030516, r2>0.9 based on 1000 Genomes CEU data).
†For the diseases PSO and T1D only results for a proxy SNP of the index SNP (rs2460554, r2>0.6) were available in ImmunoBase; no data were available for CEL and NAR for the index
SNP or proxies down to r2=0.3; for the remaining five diseases, association results for the index SNP were available.
CEL, coeliac disease; JIA, juvenile idiopathic arthritis; MS, multiple sclerosis; NAR, narcolepsy; PBC, primary biliary cirrhosis; PSO, psoriasis; RA, rheumatoid arthritis; T1D, type 1
diabetes.
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undetected population stratification may not have substantially
biased the results. In addition, the western European data sets
have been used previously in multiple similar studies nearly
always resulting in association findings in line with those from
independent GWAS (eg, refs 3 20 21). Furthermore, none of
the meta-analysis results was driven by a single outlying study
effect estimate. Thus, the presence of type 1 error in our results
due to uncorrected population stratification would imply the
same direction of bias for the majority of data sets analysed.
This would include the validation data sets tested here as well as
those included in the original study,4 the latter of which were all
adjusted for population stratification. It appears rather unlikely
that such a widespread bias would be present in the majority of
all independently recruited data sets from regionally distinct
populations. However, we cannot exclude that some results in
our validation study were affected by bias towards the null due
to subtle population stratification.
Finally, it is well known that the lead SNPs emerging from
GWAS are not necessarily the variants exerting the pathogenic
functional effects. To this end, we used PICS to generate a list of
potentially causal variants (see online supplement 2). These var-
iants were further assessed regarding their potential functional
impact by calculating the scaled ‘Combined Annotation
Dependent Depletion’ (CADD; http://cadd.gs.washington.edu/)
score,22 by annotating variants based on the Encyclopedia of
DNA Elements (ENCODE) project using HaploReg V.3 (http://
www.broadinstitute.org/mammals/haploreg/haploreg_v3.php),23
and by interrogating a recently described large-scale expression
quantitative trait locus (eQTL) database (http://genenetwork.nl/
bloodeqtlbrowser/)24 with information on transcriptome-wide
microarray-based expression data from 5311 blood samples.24
Possibly the most interesting result was obtained with SNP
rs3809006, located intronically in ETS1, which carried the
highest PICS probability of all index SNPs (29.1%) and at the
same time showed one of the highest CADD scores (10.3).
CADD scores >10 are among the top 10% of potentially patho-
genic variants of all theoretically possible 8.6 billion single
nucleotide exchanges in the human genome. A number of SNPs
in linkage disequilibrium with the seven index SNPs also showed
CADD scores >10, some of which were located in proximity to
promoter or enhancer histone marks in the thymus, blood or
brain (see online supplement 2); for instance, this included
several SNPs located 30 downstream of CD28. Notably, genetic
association—albeit at subgenome-wide significance—between
MS and CD28 had already been reported in the candidate-gene
era owing to this gene’s involvement in T cell activation.25
Interestingly, CD28 index SNP rs6435203 highly significantly
correlated with the expression of CD28 (p=1.15×10−15, see
online supplement 1: table e-4). Another of the novel genome-
wide MS SNPs identified here is rs9808753, which is located in a
region on chromosome 21q22.11 characterised by the presence
of several genes involved in the immune system response. In the
eQTL database rs9808753 was found to correlate with the
expression of several of these genes, including IL10RB
(p=3.22×10−14), IFNAR1 (p=2.57×10−7), TMEM50B
(p=3.55×10−7) and IFNAR2 (p=9.77×10−4; see online supple-
ment 1: table e-4). Online table e-5 (supplement 1) highlights
previously described functional implications of these eQTL genes
potentially underlying autoimmune disease pathophysiology and
progression. Clearly, further experimental work is needed to
characterise the potential functional impact of these and the
other MS loci newly nominated here.
In conclusion, our study is the first to establish genome-wide
significant association between risk for MS and seven new loci,
of which several show strong association with other auto-
immune diseases. Using previously generated transcriptome
data, we observed strong eQTL effects for the MS-associated
SNPs in CD28 and IFNGR2. Further fine-mapping and func-
tional studies are required to elucidate mechanisms underlying
the newly highlighted disease associations.
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